Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $185.0 million.

  • UroGen Pharma's Liabilities and Shareholders Equity fell 38.71% to $185.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $927.1 million, marking a year-over-year decrease of 3.70%. This contributed to the annual value of $285.7 million for FY2024, which is 60.23% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Liabilities and Shareholders Equity is $185.0 million, which was down 11.34% from $208.7 million recorded in Q2 2025.
  • UroGen Pharma's Liabilities and Shareholders Equity's 5-year high stood at $301.9 million during Q3 2024, with a 5-year trough of $95.4 million in Q2 2023.
  • For the 3-year period, UroGen Pharma's Liabilities and Shareholders Equity averaged around $208.3 million, with its median value being $200.6 million (2024).
  • As far as peak fluctuations go, UroGen Pharma's Liabilities and Shareholders Equity crashed by 41.64% in 2021, and later skyrocketed by 195.56% in 2024.
  • UroGen Pharma's Liabilities and Shareholders Equity (Quarterly) stood at $119.7 million in 2021, then climbed by 13.26% to $135.6 million in 2022, then soared by 31.48% to $178.3 million in 2023, then surged by 60.23% to $285.7 million in 2024, then crashed by 38.71% to $185.0 million in 2025.
  • Its last three reported values are $185.0 million in Q3 2025, $208.7 million for Q2 2025, and $247.6 million during Q1 2025.